Literature DB >> 25680443

Selection of phages and conditions for the safe phage therapy against Pseudomonas aeruginosa infections.

Victor Krylov1, Olga Shaburova, Elena Pleteneva, Sergey Krylov, Alla Kaplan, Maria Burkaltseva, Olga Polygach, Elena Chesnokova.   

Abstract

The emergence of multidrug-resistant bacterial pathogens forced us to consider the phage therapy as one of the possible alternative approaches to treatment. The purpose of this paper is to consider the conditions for the safe, long-term use of phage therapy against various infections caused by Pseudomonas aeruginosa. We describe the selection of the most suitable phages, their most effective combinations and some approaches for the rapid recognition of phages unsuitable for use in therapy. The benefits and disadvantages of the various different approaches to the preparation of phage mixtures are considered, together with the specific conditions that are required for the safe application of phage therapy in general hospitals and the possibilities for the development of personalized phage therapy.

Entities:  

Mesh:

Year:  2015        PMID: 25680443      PMCID: PMC8200895          DOI: 10.1007/s12250-014-3546-3

Source DB:  PubMed          Journal:  Virol Sin        ISSN: 1995-820X            Impact factor:   4.327


  60 in total

Review 1.  Bacteriophages in the evolution of pathogen-host interactions.

Authors:  E A Miao; S I Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

2.  Complete genome sequence of the giant virus OBP and comparative genome analysis of the diverse ΦKZ-related phages.

Authors:  Anneleen Cornelissen; Stephen C Hardies; Olga V Shaburova; Victor N Krylov; Wesley Mattheus; Andrew M Kropinski; Rob Lavigne
Journal:  J Virol       Date:  2011-11-30       Impact factor: 5.103

3.  Safety analysis of a Russian phage cocktail: from metagenomic analysis to oral application in healthy human subjects.

Authors:  Shawna McCallin; Shafiqul Alam Sarker; Caroline Barretto; Shamima Sultana; Bernard Berger; Sayeda Huq; Lutz Krause; Rodrigo Bibiloni; Bertrand Schmitt; Gloria Reuteler; Harald Brüssow
Journal:  Virology       Date:  2013-06-10       Impact factor: 3.616

4.  Comparative analysis of the widespread and conserved PB1-like viruses infecting Pseudomonas aeruginosa.

Authors:  Pieter-Jan Ceyssens; Konstantin Miroshnikov; Wesley Mattheus; Victor Krylov; Johan Robben; Jean-Paul Noben; Simon Vanderschraeghe; Nina Sykilinda; Andrew M Kropinski; Guido Volckaert; Vadim Mesyanzhinov; Rob Lavigne
Journal:  Environ Microbiol       Date:  2009-08-12       Impact factor: 5.491

5.  [Pseudolysogeny of Pseudomonas aeruginosa bacteria infected with phiKZ-like bacteriophages].

Authors:  E A Pletnev; S V Krylov; O V Shaburova; M V Burkal'tseva; K A Miroshnikov; V N Krylov
Journal:  Genetika       Date:  2010-01

6.  Art-175 is a highly efficient antibacterial against multidrug-resistant strains and persisters of Pseudomonas aeruginosa.

Authors:  Yves Briers; Maarten Walmagh; Barbara Grymonprez; Manfred Biebl; Jean-Paul Pirnay; Valerie Defraine; Jan Michiels; William Cenens; Abram Aertsen; Stefan Miller; Rob Lavigne
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

7.  Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections.

Authors:  Marine Henry; Rob Lavigne; Laurent Debarbieux
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

8.  [Expression of the genome of Mu-like phage D3112 specific for Pseudomonas aeruginosa in Escherichia coli and Pseudomonas putida cells].

Authors:  T G Plotnikova; L A Kulakov; E N Eremenko; T V Fedorova; V N Krylov
Journal:  Genetika       Date:  1982-07

9.  [Genome conservatism of phiKMV-like bacteriophages (T7 supergroup) active against Pseudomonas aeruginosa].

Authors:  M V Burkal'tseva; E A Pleteneva; O V Shaburova; V A Kadykov; V N Krylov
Journal:  Genetika       Date:  2006-01

10.  Differential infection properties of three inducible prophages from an epidemic strain of Pseudomonas aeruginosa.

Authors:  Chloe E James; Joanne L Fothergill; Amanda J Hall; Jennifer Cottell; Michael A Brockhurst; Craig Winstanley
Journal:  BMC Microbiol       Date:  2012-09-21       Impact factor: 3.605

View more
  6 in total

1.  Bacteriophages, revitalized after 100 years in the shadow of antibiotics.

Authors:  Hongping Wei
Journal:  Virol Sin       Date:  2015-02       Impact factor: 4.327

Review 2.  Modular Approach to Select Bacteriophages Targeting Pseudomonas aeruginosa for Their Application to Children Suffering With Cystic Fibrosis.

Authors:  Victor Krylov; Olga Shaburova; Elena Pleteneva; Maria Bourkaltseva; Sergey Krylov; Alla Kaplan; Elena Chesnokova; Leonid Kulakov; Damian Magill; Olga Polygach
Journal:  Front Microbiol       Date:  2016-10-13       Impact factor: 5.640

3.  Use of a Primary Epithelial Cell Screening Tool to Investigate Phage Therapy in Cystic Fibrosis.

Authors:  Stephanie Trend; Barbara J Chang; Mark O'Dea; Stephen M Stick; Anthony Kicic
Journal:  Front Pharmacol       Date:  2018-11-28       Impact factor: 5.810

4.  vB_PaeM_MIJ3, a Novel Jumbo Phage Infecting Pseudomonas aeruginosa, Possesses Unusual Genomic Features.

Authors:  Mohammed Imam; Bandar Alrashid; Faizal Patel; Ahmed S A Dowah; Nathan Brown; Andrew Millard; Martha R J Clokie; Edouard E Galyov
Journal:  Front Microbiol       Date:  2019-11-28       Impact factor: 5.640

Review 5.  Phage Revolution Against Multidrug-Resistant Clinical Pathogens in Southeast Asia.

Authors:  Mark B Carascal; Donna May Dela Cruz-Papa; Roland Remenyi; Mely Cherrylynne B Cruz; Raul V Destura
Journal:  Front Microbiol       Date:  2022-01-27       Impact factor: 5.640

Review 6.  Black box of phage-bacterium interactions: exploring alternative phage infection strategies.

Authors:  Sari Mäntynen; Elina Laanto; Hanna M Oksanen; Minna M Poranen; Samuel L Díaz-Muñoz
Journal:  Open Biol       Date:  2021-09-15       Impact factor: 6.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.